Fig. 3From: Synthesis and bio-molecular study of (+)-N-Acetyl-α-amino acid dehydroabietylamine derivative for the selective therapy of hepatocellular carcinomaCell cycle results after 24, 48 and 72 h of DAAD2 (5 μM concentration) treated Hep3B cells and DMSO controls (up to 0.1%) as untreated cells. Comparative to un-treated Hep3B cells, noticeable changes in sub-G1/G0 and G2/M phase of DAAD2 treated Hep3B cells are shownBack to article page